Enliven Therapeutics (ELVN) to Release Quarterly Earnings on Tuesday

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect Enliven Therapeutics to post earnings of ($0.51) per share for the quarter.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Down 2.6 %

Shares of ELVN stock traded down $0.52 on Tuesday, reaching $19.87. The company had a trading volume of 26,456 shares, compared to its average volume of 259,003. The stock has a market capitalization of $974.94 million, a PE ratio of -10.55 and a beta of 1.07. The business's 50-day moving average is $19.17 and its 200 day moving average is $22.28. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.03.

Insider Buying and Selling

In related news, insider Joseph P. Lyssikatos sold 5,030 shares of the business's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $20.07, for a total transaction of $100,952.10. Following the sale, the insider now directly owns 992,658 shares in the company, valued at approximately $19,922,646.06. The trade was a 0.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the transaction, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. The trade was a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,111 shares of company stock worth $1,539,266. Insiders own 29.20% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.